Please ensure Javascript is enabled for purposes of website accessibility

Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors

By Cory Renauer - Updated Dec 21, 2017 at 1:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This already well-performing biotech stock could have a lot more climbing to do.

Exelixis, Inc. (EXEL -0.81%) has already delivered big gains this year, but there could be a few untapped veins in this biotech gold mine. We'll need to tread lightly because a great deal of success is already baked into the price, but a few catalysts on the horizon could send this stock soaring again in 2018. 

In a nutshell, there's a good chance the number of patients eligible to receive this company's pricey cancer drugs could rise several fold. Here's a closer look at a few key factors that could dislodge some shiny nuggets in the years ahead.

Stellar results

Exelixis' lead drug, Cabometyx, is currently limited to certain patients with kidney and thyroid cancer, and Exelixis needs to expand the drug's addressable patient population if its stock is to rise from present levels. The company is fortunate to have promising data from the Celestial trial that ought to persuade the FDA to expand its indication to include a large group of liver cancer patients with a dearth of effective treatment options.

Patient giving thumbs up sign in front of a doctor.

Image source: Getty Images.

The drug significantly improved survival odds among patients with advanced-stage hepatocellular carcinoma (HCC), the most common form of liver cancer, in a pivotal trial earlier this fall. Exelixis intends to submit an application to the FDA that would expand the Cabometyx drug label to include advanced-stage HCC patients in the first quarter of 2018. Given the results in hand, an approval seems likely.

While some liver cancer sales are already baked into Exelixis' $7.7 billion market cap, the population is large and underserved. Liver cancer is expected to claim the lives of around 29,000 Americans this year, and an estimated 700,000 worldwide.

To the front of the line

Freshly diagnosed cancer patients tend to stay on their first therapy longer than on subsequent treatments. This is why Exelixis investors should be just as excited about Cabometyx's recent move to the front of the kidney cancer treatment line as they are about its chance to become a new HCC option.

Pfizer's Sutent currently holds lead in the first-line position, but Exelixis' drug could overtake it. Cabometyx lowered newly diagnosed patients' risk of death or worsening disease by 52% compared with the standard first-line treatment.

A second chance for Cotellic

With all the buzz around Cabometyx, it's easy to forget Exelixis has a second commercial-stage drug. In 2015, Cotellic earned FDA approval to treat a genetically defined group of melanoma patients in combination with Roche's (RHHBY 1.09%) Zelboraf.

Cotellic royalties from the Swiss drugmaker reached just $5 million in the first nine months of 2017, but a recent legal settlement could boost this figure in the years ahead. Exelixis recently reworked their old collaboration agreement in a manner that paves the way for further combinations.

One of the first new combinations for Cotellic could include Roche's immunotherapy, Tecentriq. Exelixis' partner is conducting three late-stage trials with Cotellic in combination with its increasingly popular drug and investors will want to keep their eyes open for results due around the middle of 2018.

Scientists at work, reviewing data on a clipboard in a lab.

Image source: Getty Images.

Putting it together

Exelixis reported a tremendous 126% rise in third-quarter product sales to an annualized run rate of $386 million. That's nothing to sneeze at, but it's hardly enough to support the stock's recent $7.7 billion market cap without a ton of growth in the quarters ahead. That means Exelixis will probably need a lot more than FDA approvals to persuade the market to lift its stock price much further.

Although Cotellic might not have blockbuster potential, a successful label expansion, possibly as part of a new combination therapy, could boost high-margin royalty revenue received from Roche above $200 million in the years ahead. That's small potatoes next to peak contributions expected from Cabometyx. If the tablets become standard treatments for the liver and kidney cancer indications they're currently aimed at, I think annual sales of the drug could pass $3 billion by 2022.

A lot can go wrong between now and then, but it looks as if Exelixis has everything it needs to become a gold mine for patient growth investors.

Editor's note: The original version of this article stated that Cabometyx had not yet been approved. It has been updated to reflect an approval, which came on December 19, 2017.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exelixis, Inc. Stock Quote
Exelixis, Inc.
$20.77 (-0.81%) $0.17
Roche Holding AG Stock Quote
Roche Holding AG
$41.81 (1.09%) $0.45
Pfizer Inc. Stock Quote
Pfizer Inc.
$50.91 (0.49%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.